<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888650</url>
  </required_header>
  <id_info>
    <org_study_id>38RC21.054</org_study_id>
    <nct_id>NCT04888650</nct_id>
  </id_info>
  <brief_title>Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema</brief_title>
  <acronym>BESQAOH</acronym>
  <official_title>Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      8 years after the establishment of the therapeutic education program and 14 years after the&#xD;
      creation of the National Reference Center for Angioedemas (CREAK), it is necessary to make an&#xD;
      inventory in 2021 on the disease experienced by the patient with an assessment the needs and&#xD;
      expectations of HAE patients. This assessment would make it possible to see the evolution of&#xD;
      these needs and to adjust the price for the overall cost of children and adults in France. It&#xD;
      may also allow a comparison of the requests expressed during a similar survey in another&#xD;
      French-speaking region such as Quebec.&#xD;
&#xD;
      Main objective is to know the needs and the current satisfaction of the needs, with regard to&#xD;
      the disease and the treatment of the targeted patients of hereditary angioedema (HAE)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the needs and the current satisfaction of the needs, with regard to the disease and the treatment of patients with hereditary angioedema (HAE)</measure>
    <time_frame>baseline</time_frame>
    <description>questionnaire To know the needs and the current satisfaction of the needs, with regard to the disease and the treatment of patients with hereditary angioedema (HAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparaison of results with quebec</measure>
    <time_frame>baseline</time_frame>
    <description>Comparison of the results of the French questionnaire, only the questions adapted from the Quebec questionnaire, with the results of the Quebec survey conducted by Jean-Nicolas Boursiquot in 2018.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>angiodema hereditary patients</arm_group_label>
    <description>Patient with HAE with or without C1 inhibitor deficiency will respond to an electronic questionnaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>electronic questionnaire</description>
    <arm_group_label>angiodema hereditary patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with HAE with or without C1 inhibitor deficiency&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with HAE with or without C1 inhibitor deficiency&#xD;
&#xD;
          -  Patient over 15 or parents of a child under 15 with HAE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient opposed to the use of their data or refusing to answer the questionnaire&#xD;
&#xD;
          -  Adult patients protected by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>isabelle boccon gibod, ph</last_name>
    <phone>+33 4 76 76 76 40</phone>
    <email>iboccon-gibod@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>melanie arnaud</last_name>
    <phone>+33 4 76 76 78 38</phone>
    <email>marnaud3@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHUGA</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Boccon-Gibod</last_name>
    </contact>
    <contact_backup>
      <last_name>MÃ©lanie Arnaud</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

